02/06/2026
We are feeling inspired after attending yesterday’s Aspire Biosciences CNS Networking Event alongside so many dedicated rare disease organisations.
It was encouraging to see the rare disease community out in force and to hear about growing pharmaceutical interest in rare conditions, including exciting and innovative research approaches that could help drive future treatment development and improve outcomes for patients and families.
Events like these provide valuable opportunities to build connections, share experiences, and ensure that the voices of rare disease communities remain at the heart of research and innovation.
We are particularly encouraged by the interest shown in GLUT1 Deficiency and look forward to continuing conversations with companies and researchers who are committed to advancing understanding, treatment options, and opportunities for collaboration within our community.
Thank you to Aspire Biosciences for bringing together such a diverse and passionate group of stakeholders. The future is built through partnership, and we are excited about the possibilities ahead.